Literature DB >> 20658166

Candida rugosa: a possible emerging cause of candidaemia in trauma patients.

B Behera1, R I Singh, I Xess, P Mathur, F Hasan, M C Misra.   

Abstract

INTRODUCTION: Candida rugosa appears to be emerging as a distinctive cause of candidaemia in recent years. Candidaemia due to this species is important to recognise because of its decreased susceptibility to azoles.
MATERIALS AND METHODS: We retrospectively evaluated a cluster of C. rugosa candidaemia occurring in critically ill trauma patients from a level I trauma centre of India. During the period from July 2008 to September 2009, a total of 28 blood samples from 19 patients were found to be positive for C. rugosa. Genetic relatedness among 17 C. rugosa isolates were characterised by the random amplified polymorphic DNA (RAPD) assay using M13 primers. These isolates were also characterised for their susceptibility to four antifungal agents, amphotericin B, fluconazole, flucytosine and voriconazole.
RESULTS: In our study, 21% of C. rugosa isolates were resistant to fluconazole, whereas 100% susceptibility to amphotericin B, flucytosine and voriconazole was noted. Thirteen out of the 19 patients (68.4%) with C. rugosa candidaemia died. Of these, six had received antifungal therapy after confirmation of fungaemia. DISCUSSION: Prior to this cluster, C. rugosa had never been identified as a cause of infection at our centre. Due to the retrospective nature of the evaluation of these cases, the source of this possible outbreak could not be traced. Nevertheless, to the best of our knowledge, this is the largest cluster of cases of C. rugosa candidaemia reported from a single institution in the English literature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658166     DOI: 10.1007/s15010-010-0044-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Comparative study of the new colorimetric VITEK 2 yeast identification card versus the older fluorometric card and of CHROMagar Candida as a source medium with the new card.

Authors:  C L Aubertine; M Rivera; S M Rohan; D H Larone
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature.

Authors:  Lucio R Minces; Ken S Ho; Peter J Veldkamp; Cornelius J Clancy
Journal:  Scand J Infect Dis       Date:  2009

4.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

5.  Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; A L Colombo; C Kibbler; K P Ng; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

Review 6.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

7.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Candida rugosa in immunocompromised infection. Case reports, drug susceptibility, and review of the literature.

Authors:  A M Sugar; D A Stevens
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

9.  Identification of clinical strains of Candida albicans by DNA fingerprinting with the polymerase chain reaction.

Authors:  G Schönian; O Meusel; H J Tietz; W Meyer; Y Gräser; I Tausch; W Presber; T G Mitchell
Journal:  Mycoses       Date:  1993 May-Jun       Impact factor: 4.377

10.  Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida.

Authors:  Duane R Hospenthal; Miriam L Beckius; Karon L Floyd; Lynn L Horvath; Clinton K Murray
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-01-03       Impact factor: 3.944

View more
  3 in total

1.  Chemical composition profiling and antifungal activity of the essential oil and plant extracts of Mesembryanthemum edule (L.) bolus leaves.

Authors:  Beauty Etinosa Omoruyi; Anthony Jide Afolayan; Graeme Bradley
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-06-04

2.  Rapid identification of yeast isolates from clinical specimens in critically ill trauma ICU patients.

Authors:  Neetu Jain; Purva Mathur; Mahesh Chandra Misra; Bijayini Behera; Immaculata Xess; Satya Priya Sharma
Journal:  J Lab Physicians       Date:  2012-01

3.  The inhibitory effect of Mesembryanthemum edule (L.) bolus essential oil on some pathogenic fungal isolates.

Authors:  Beauty E Omoruyi; Anthony J Afolayan; Graeme Bradley
Journal:  BMC Complement Altern Med       Date:  2014-05-23       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.